glutathione mold and Mycotoxin Illness: Its Connection to ME/CFS, MCAS, and Chronic Symptoms What You ACTUALLY Need to

In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday

Records: Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction

Kim S, Kwon J (2014) Thymosin beta 4 improves dermal burn wound healing via downregulation of receptor of advanced glycation end products in db/db mice

Research institutions studying metabolic peptides have documented various responses to AOD 9604 administration